ARTICLE | Company News
Novartis, Questcor deal
July 14, 2014 7:00 AM UTC
Questcor completed its acquisition of exclusive, worldwide rights, outside of 13 EU countries, to develop and commercialize Synacthen tetracosactrin and its extended-release formulation Synacthen Depot from Novartis (see BioCentury, June 17, 2013). ...